180 CHF CHF 180.00
AG-CR1-3903-M0011 mgCHF 180.00
AG-CR1-3903-M0055 mgCHF 640.00
|Purity Chemicals||≥95% (HPLC)|
|Appearance||Off white solid.|
|Solubility||Soluble in DMSO, methanol or ethanol.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =7.5nM). Displays high selectivity over HDAC1-9 (IC50=1-10µM).
- Shows improved brain bioavailability compared to tubastatin A (Prod. No. AG-CR1-3900).
- Induces hyperacetylation of α-tubulin in brain without concurrently altering the acetylation of histones.
- Shows antidepressant activity.
- HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC: S. Mithraprabhu, et al.; Br. J. Haematol. 162, 559 (2013)
- Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer: J.S. Riley, et al.; Cell Death Dis. 4, e951 (2013)
- RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth: K.A. Wilson-Edell, et al.; Oncotarget 5, 5165 (2014)
- Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability: J. Jochems, et al.; Neuropsychopharmacol. 39, 389 (2014)